I
IX Biopharma Ltd
SGX:42C
IX Biopharma Ltd
SGX:42C
Price:
0.191
SGD
-4.5%
Market Closed
Market Cap:
S$183.3m
Balance Sheet
Balance Sheet Decomposition
IX Biopharma Ltd
IX Biopharma Ltd
Balance Sheet Decomposition is not available for
IX Biopharma Ltd
IX Biopharma Ltd
Balance Sheet
IX Biopharma Ltd
IX Biopharma Ltd
Currency: SGD
| Jun-2012 | Jun-2013 | Jun-2014 | Jun-2015 | Jun-2016 | Jun-2017 | Jun-2018 | Jun-2019 | Jun-2020 | Jun-2021 | Jun-2022 | Jun-2023 | Jun-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
0
|
8
|
12
|
9
|
31
|
31
|
21
|
16
|
6
|
6
|
13
|
7
|
2
|
1
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
0
|
0
|
|
| Cash Equivalents |
0
|
8
|
12
|
9
|
31
|
31
|
21
|
16
|
6
|
6
|
13
|
0
|
2
|
1
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
1
|
2
|
5
|
3
|
2
|
1
|
1
|
2
|
2
|
3
|
3
|
2
|
|
| Accounts Receivables |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
|
| Other Receivables |
0
|
0
|
1
|
0
|
4
|
2
|
1
|
1
|
1
|
2
|
1
|
2
|
2
|
1
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Total Current Assets |
0
|
9
|
13
|
11
|
37
|
35
|
24
|
19
|
8
|
9
|
17
|
11
|
7
|
4
|
|
| PP&E Net |
0
|
0
|
3
|
2
|
8
|
8
|
8
|
8
|
8
|
9
|
8
|
8
|
8
|
7
|
|
| PP&E Gross |
0
|
0
|
3
|
2
|
8
|
8
|
8
|
8
|
8
|
9
|
8
|
8
|
8
|
7
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
1
|
2
|
2
|
2
|
3
|
5
|
4
|
5
|
5
|
5
|
|
| Intangible Assets |
0
|
0
|
3
|
2
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
4
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
0
N/A
|
9
+2 205%
|
19
+115%
|
15
-18%
|
46
+199%
|
44
-4%
|
33
-25%
|
27
-19%
|
17
-36%
|
19
+11%
|
29
+51%
|
25
-13%
|
15
-41%
|
11
-23%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
0
|
0
|
0
|
1
|
1
|
1
|
4
|
0
|
1
|
1
|
0
|
0
|
5
|
6
|
|
| Accrued Liabilities |
0
|
0
|
1
|
2
|
1
|
2
|
3
|
2
|
2
|
2
|
2
|
3
|
2
|
3
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
4
|
3
|
3
|
4
|
|
| Other Current Liabilities |
0
|
0
|
1
|
2
|
1
|
1
|
1
|
0
|
0
|
0
|
2
|
1
|
1
|
1
|
|
| Total Current Liabilities |
0
|
1
|
4
|
4
|
3
|
4
|
7
|
3
|
3
|
4
|
8
|
7
|
7
|
9
|
|
| Long-Term Debt |
0
|
0
|
1
|
0
|
4
|
4
|
4
|
4
|
3
|
3
|
1
|
1
|
2
|
2
|
|
| Deferred Income Tax |
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
|
| Other Liabilities |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
0
N/A
|
1
+65%
|
6
+889%
|
5
-14%
|
8
+54%
|
9
+9%
|
12
+34%
|
6
-46%
|
7
+10%
|
7
+5%
|
9
+23%
|
9
+3%
|
10
+13%
|
11
+6%
|
|
| Equity | |||||||||||||||
| Common Stock |
4
|
11
|
21
|
29
|
65
|
70
|
71
|
72
|
72
|
83
|
94
|
97
|
97
|
101
|
|
| Retained Earnings |
4
|
6
|
9
|
19
|
27
|
34
|
50
|
53
|
63
|
72
|
76
|
85
|
97
|
107
|
|
| Other Equity |
0
|
4
|
0
|
0
|
1
|
0
|
0
|
2
|
1
|
0
|
2
|
4
|
4
|
6
|
|
| Total Equity |
0
N/A
|
8
+81 400%
|
13
+57%
|
10
-20%
|
38
+273%
|
36
-7%
|
22
-40%
|
20
-5%
|
10
-50%
|
12
+15%
|
20
+69%
|
16
-20%
|
4
-73%
|
0
-92%
|
|
| Total Liabilities & Equity |
0
N/A
|
9
+2 205%
|
19
+115%
|
15
-18%
|
46
+199%
|
44
-4%
|
33
-25%
|
27
-19%
|
17
-36%
|
19
+11%
|
29
+51%
|
25
-13%
|
15
-41%
|
11
-23%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
546
|
546
|
546
|
546
|
622
|
647
|
651
|
652
|
652
|
697
|
760
|
775
|
768
|
888
|
|
Switch to:
Switch to:
See Also
Discover More
